ARTA
FRTX

A.R.T. Advisors’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

A.R.T. Advisors’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-69
Closed -$19K – 1797
2019
Q2 		$19K Sell
69
-71
-51% -$23.8K ﹤0.01% 1299
2019
Q1 		$53K Buy
+140
New +$46.9K ﹤0.01% 1213
2018
Q4 		– Sell
-99
Closed -$42K – 1752
2018
Q3 		$42K Buy
99
+37
+60% +$15.6K ﹤0.01% 1325
2018
Q2 		$22K Sell
62
-43
-41% -$20.2K ﹤0.01% 1362
2018
Q1 		$47K Buy
+105
New +$52.1K ﹤0.01% 1405
2017
Q4 		– Sell
-43
Closed -$32K – 1742
2017
Q3 		$32K Sell
43
-12
-22% -$9.49K ﹤0.01% 1278
2017
Q2 		$47K Sell
55
-9
-14% -$6.58K ﹤0.01% 1309
2017
Q1 		$44K Buy
64
+30
+88% +$21.2K ﹤0.01% 1332
2016
Q4 		$24K Buy
+34
New +$27.6K ﹤0.01% 1238
2015
Q3 		– Sell
-20
Closed -$43K – 1663
2015
Q2 		$43K Buy
+20
New +$62.7K ﹤0.01% 1415
2014
Q1 		– Sell
-15
Closed -$55K – 1608
2013
Q4 		$55K Sell
15
-5
-25% -$18.9K ﹤0.01% 1225
2013
Q3 		$79K Sell
20
-5
-20% -$37.5K ﹤0.01% 1238
2013
Q2 		$243K Buy
+25
New +$277K 0.01% 1109

Other funds holding FRTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

A.R.T. Advisors's FRTX Position: Q3 2019 in Review

A.R.T. Advisors sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2019, closing a stake of 69 shares — an estimated $19K sold.

A.R.T. Advisors first reported a position in FRTX in Q2 2013 and held it in 13 quarters. The position peaked at $243K in Q2 2013. 17 funds tracked by Wall St. Rank hold FRTX as of Q3 2019.

  • A.R.T. Advisors reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 69 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $19K.
  • A.R.T. Advisors first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 13 quarters.
  • A.R.T. Advisors's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $243K in Q2 2013.
  • 17 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2019.

Based on A.R.T. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.